Alector (ALEC) AI Stock Analysis

• Market Cap: $246.11M
• Dividend Yield: N/A
• Average Volume (3M): 898.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.05
• Revenue Growth: 12.26%
• EPS Growth: 37.36%
• Country: US
• Employees: 175
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.34
• Shares Outstanding: 110,362,580
• 10 Day Avg. Volume: 999,438
• 30 Day Avg. Volume: 898,289
• PEG Ratio: -0.09
• Price to Book (P/B): 5.24
• Price to Sales (P/S): 7.63
• P/FCF Ratio: -0.87
• Enterprise Value/Market Cap: 0.88
• Enterprise Value/Revenue: 10.29
• Enterprise Value/Gross Profit: 11.53
• Enterprise Value/Ebitda: -1.59
• 1Y Price Target: $2.88
• Price Target Upside: 29.15% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 7
• EPS Forecast (FY): -0.85
• Revenue Forecast (FY): $38.10M

• Rating: 46 Neutral
• Price Target: $2.00 ▼(-10.31% Downside)
• Action: Reiterated Date: 02/26/26
• Date: Action: Reiterated 02/26/26

The score is held down primarily by weak financial performance, including sustained losses, heavy recent cash burn, and a weakened 2025 balance-sheet picture. Technicals are supportive on trend but appear overextended, while valuation is constrained by negative earnings and no dividend. A positive CFO appointment is a modest offset.

Positive Factors

Focused immuno‑neurology pipeline

Alector's concentrated scientific focus on innate immune function and neuroinflammation creates durable differentiation versus broad-based biotechs. A clear therapeutic niche (antibody-based neurodegeneration programs) supports long-term IP concentration, specialized expertise, and potential platform leverage across multiple indications if clinical proof emerges.

Partnership-driven funding model

Reliance on upfronts, research funding, milestones and potential royalties is structurally beneficial for a clinical-stage firm: it provides non‑dilutive or milestone-tied capital infusions that can extend runway, share development risk with partners, and align incentives across programs while R&D progresses toward de-risking events.

Permanent CFO appointment

Installing a permanent CFO is a durable governance improvement: it strengthens financial planning, capital‑market execution and cost discipline—critical given ongoing cash burn. A stable finance lead can optimize funding strategies, negotiate partner deals, and improve investor communications over multiple financing cycles.

Negative Factors

Persistent negative operating and free cash flow

Sustained negative operating and free cash flow across multiple years creates structural funding risk: the company must repeatedly access capital markets or partner funding, which dilutes shareholders or increases leverage. Ongoing cash burn limits flexibility to advance multiple programs and raises long-term execution uncertainty absent durable cash generation.

Sharp revenue deterioration in 2025

A pronounced revenue drop materially reduces available resources to cover fixed R&D and G&A costs, worsening operating leverage. For a clinical-stage biotech that depends on milestone and collaboration receipts, a sharp, persistent decline signals timing or partner issues that can prolong funding needs and impede steady program advancement.

Balance-sheet weakening and higher leverage

Debt-to-equity rising to ~1.18 and falling equity reduce financial flexibility and increase refinancing and covenant risk. Higher leverage limits ability to secure non-dilutive financing, raises interest burden, and constrains strategic options if clinical timelines slip—making long-term program funding more costly and uncertain.

Alector Business Overview & Revenue Model

Company Description

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

How the Company Makes Money

Alector primarily generates revenue through collaboration and licensing arrangements rather than product sales, as it is a clinical-stage company and does not have commercialized therapies. These arrangements typically produce revenue from (1) upfront payments received at the start of a partnership, (2) research funding and cost-sharing or reimbursement for development activities performed under the collaboration, (3) milestone payments earned upon achieving specified clinical, regulatory, or commercial objectives, and (4) potential royalties on net sales if a partnered product is successfully commercialized. The company has historically relied on such partnership-related revenue and on raising capital (e.g., equity offerings) to fund operations; however, capital raises are financing activities and not reported as revenue.

Alector Financial Statement Overview

Summary

Financial profile is weak: persistent operating/net losses, a sharp 2025 revenue decline (~69.5% YoY), and deeply negative operating/free cash flow in 2022–2025 indicate continued funding risk. Balance sheet leverage was historically modest but appears to weaken in 2025 as equity falls and debt-to-equity rises (~1.18).

Income Statement

Profitability remains weak, with sizable operating and net losses across all reported years. Revenue has been volatile and recently deteriorated sharply (2025 annual revenue down ~69.5% year-over-year), which magnifies fixed-cost pressure and keeps margins deeply negative. A positive is that gross profit has been strong in several years (e.g., 2022–2024), but that has not translated into sustainable bottom-line improvement.

Balance Sheet

Leverage looks manageable in most years with relatively modest debt versus equity (debt-to-equity ~0.16–0.34 from 2021–2024), but 2025 shows a clear balance-sheet weakening as equity falls materially and debt-to-equity rises to ~1.18. Returns on equity are consistently negative, reflecting ongoing losses. Overall asset levels have also trended down versus prior peaks, suggesting reduced financial flexibility over time.

Cash Flow

Cash generation is a key concern: operating cash flow and free cash flow are deeply negative in 2022–2025, including substantial cash burn in 2024 and 2025. While 2021 showed strong positive operating and free cash flow, that performance did not persist. Free cash flow has generally moved in the wrong direction (negative growth in multiple years), indicating continued funding needs if losses persist.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	21.05M	100.56M	97.06M	133.62M	207.09M
Gross Profit	11.38M	100.56M	88.21M	133.62M	17.68M
EBITDA	-133.10M	-136.16M	-142.89M	-129.36M	-29.05M
Net Income	-142.93M	-119.05M	-130.39M	-133.31M	-36.33M
Balance Sheet
Total Assets	293.24M	468.30M	621.83M	787.65M	814.66M
Cash, Cash Equivalents and Short-Term Investments	256.02M	413.40M	548.86M	712.85M	735.25M
Total Debt	36.23M	42.52M	38.92M	43.33M	47.60M
Total Liabilities	262.59M	341.50M	487.67M	573.21M	513.93M
Stockholders Equity	30.65M	126.80M	134.16M	214.44M	300.72M
Cash Flow
Free Cash Flow	-184.07M	-231.16M	-186.54M	-24.45M	295.30M
Operating Cash Flow	-184.03M	-229.91M	-184.16M	-20.33M	298.55M
Investing Cash Flow	196.60M	107.13M	101.92M	-159.01M	-49.66M
Financing Cash Flow	20.21M	81.54M	2.55M	4.51M	30.30M

Alector Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.23
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALEC, the sentiment is Positive. The current price of 2.23 is above the 20-day moving average (MA) of 2.18, above the 50-day MA of 1.99, and above the 200-day MA of 1.93, indicating a bullish trend. The MACD of 0.08 indicates Positive momentum. The RSI at 54.18 is Neutral, neither overbought nor oversold. The STOCH value of 42.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALEC.

Alector Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NMRA	52 Neutral	$472.86M	-1.30	-113.81%	―	―	20.71%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VOR	50 Neutral	$569.65M	-0.10	274.58%	―	―	-1072.48%
ACIU	47 Neutral	$328.49M	-3.73	-101.60%	―	-89.01%	-86.17%
ALEC	46 Neutral	$246.11M	-1.12	-224.96%	―	12.26%	37.36%
FHTX	45 Neutral	$297.02M	-4.58	105.48%	―	-3.91%	37.89%